Evidence map›Paper›PMID 40900321›Full record

SynthesisEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Efficacy and safety of superior laryngeal nerve block in neurogenic cough: A systematic review and meta-analysis.

Amal Binhazzaa

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Amal BinhazzaaDepartment of Otolaryngology-Head and Neck Surgery, Collage of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia. ambinhazzaa@imamu.edu.sa.ORCID http://orcid.org/0000-0002-5098-439X

Funding

Al-Imam Muhammad Ibn Saud Islamic University IMSIU-DDRSP2501
6 · The paper itself

Abstract

backgroundNeurogenic cough is a chronic condition characterized by persistent coughing that is unresponsive to conventional treatments. It is thought to result from sensory neuropathy of the laryngeal nerves, leading to heightened cough reflex sensitivity. Current management strategies include neuromodulating medications and speech therapy, but these are often ineffective or associated with significant side effects. Superior laryngeal nerve (SLN) block has emerged as a minimally invasive alternative, hypothesized to modulate sensory feedback and disrupt maladaptive cough signaling pathways. This systematic review and meta-analysis aimed to assess the efficacy and safety of SLN block in the treatment of neurogenic cough.

methodsA comprehensive literature search was conducted using PubMed, Web of Science, and Scopus from inception to January 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies evaluating SLN block for neurogenic cough. Outcomes analyzed included the Cough Severity Index (CSI), Leicester Cough Questionnaire (LCQ) scores, improvement rates, and incidence of serious adverse events. Data synthesis was performed using a random-effects model, and heterogeneity was assessed using the I² statistic.

resultsNine studies (eight retrospective and one RCT) with sample sizes ranging from 16 to 209 patients were included. SLN block resulted in a significant reduction in CSI scores (MD = -11.2, 95% CI: -15.32, -7.08) and a significant improvement in LCQ scores (MD = 2.23, 95% CI: 0.6, 3.85, p = 0.007). The intervention showed a high incidence of symptom improvement (effect estimate = 0.803, 95% CI: 0.722, 0.883) with a low rate of serious adverse events (effect estimate = 0.015, 95% CI: 0.0001, 0.03).

conclusionSLN block is a promising and safe intervention for neurogenic cough, demonstrating significant symptom relief and minimal adverse effects. However, further RCTs are needed to confirm long-term efficacy and establish standardized treatment protocols.

Indexed as

CoughLaryngeal NervesNerve BlockHumansTreatment OutcomeEfficacyMeta-analysisNeurogenic coughSafetySuperior laryngeal nerve block

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.